The National Institute for Health and Care Excellence has issued draft guidelines concluding that Biomarin’s Brineura is not a cost-effective treatment option for patients with the ultra rare disorder Batten disease.
News
Plaque psoriasis patients to get NHS access to LEO’s Kyntheum
Patients with severe plaque psoriasis are a step closer to getting NHS funded access to LEO Pharma’s Kyntheum, after cost regulators published final draft guidelines backing the drug.
Scotland endorses five new therapies for NHS use
Five new medicines are to be funded by the NHS in Scotland, bringing new treatment options for cancer, multiple sclerosis and rheumatoid arthritis, as well as a new contraceptive.
SBRI comp hands over £1m to cancer screening innovations
SBRI Healthcare has unveiled the winners in the latest round of its development awards, supporting high potential cancer screening solutions.
Vertex secures US approval for Symdeko
US regulators have approved Vertex’ Symdeko, a combination of Kalydeco (ivacaftor) and tezacaftor, to treat certain patients with cystic fibrosis (CF).
EU approves Novo’s once-weekly diabetes therapy
European regulators have issued a green light for Novo Nordisk’s once-weekly diabetes therapy Ozempic.
NICE backs EUSA’s kidney cancer drug Fotivda
The National Institute for Health and Care Excellence (NICE) has published draft guidelines backing use of EUSA Pharma’s Fotivda as a first-line treatment option for advanced renal cell carcinoma.
Liverpool Uni researchers given £1.5m for pancreatic cancer study
Scientists at the University of Liverpool have been awarded £1.5 million by Cancer Research UK for work that aims to boost understanding about pancreatic cancer.
Boehringer ends development of Alzheimer’s candidate
Boehringer Ingelheim is ending development of BI 409306 in Alzheimer’s disease on disappointing mid-stage trial data.
Roche’s Gazyvaro gets NICE nod for high-risk lymphoma patients
Cost regulators for NHS treatments in England and Wales have now recommended funding for Roche’s Gazyvaro for some patients with untreated follicular lymphoma, after the submission of new data by the company.
NICE asks Tesaro to submit CDF application for Zejula
Tesaro has been asked by NICE to submit a proposal for Zejula use on the National Health Service via the Cancer Drugs Fund for maintenance treatment of patients with relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer.
Liver cancer patients barred from NHS access to Bayer’s Stivarga
It is now looking very unlikely that patients with liver cancer will get access to Bayer’s Stivarga on the NHS, after cost regulators issued final draft guidelines rejecting funding for the drug in this setting.
UK launch for Bayer’s five-year contraceptive Kyleena
A new long-acting reversible contraception method offering protection from unplanned pregnancy for up to five years has been launched in the UK.
ViiV kicks off PhIII trial of two-drug HIV regimen
ViiV Healthcare, an HIV specialist firm majority owned by GlaxoSmithKline, has announced the launch of a late-stage study investigating the effectiveness of a two-drug regimen programme in patients with HIV.
Biogen reveals Tysabri failure in stroke trial
Biogen has confirmed that it will not pursue further development of Tysabri in acute ischemic stroke (AIS) after a mid-stage study missed primary and secondary efficacy goals.
